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Background
Hydroxyethyl starch (HES) is widely used for ﬂ uid resus-
citation in ICUs, but its safety and eﬃ  cacy have not been 
established in patients with severe sepsis.
Methods
Objective: To assess the eﬀ ects of HES 130/0.4 compared 
with a balanced crystalloid solution on mortality and 
end-stage kidney failure in patients with severe sepsis.
Design: Multicenter, parallel-group, blinded, randomized 
clinical trial, in patients with severe sepsis.
Interventions: Patients with severe sepsis admitted to the 
ICU received ﬂ uid resuscitation with either 6% HES 
130/0.42 (Tetraspan) or Ringer’s acetate at a dose of up to 
33 ml per kilogram of ideal body weight per day.
Results
Of the 804 patients who underwent randomization, 798 
were included in the modiﬁ ed intention-to-treat popu-
lation. Th e two intervention groups had similar baseline 
characteristics. At 90 days after randomization, 201 of 
398 patients (51%) assigned to HES 130/0.42 had died, as 
compared with 172 of 400 patients (43%) assigned to 
Ringer’s acetate (relative risk, 1.17; 95% conﬁ dence 
interval (CI), 1.01 to 1.36; P  =  0.03); 1 patient in each 
group had end-stage kidney failure. In the 90-day period, 
87 patients (22%) assigned to HES 130/0.42 were treated 
with renal replacement therapy versus 65 patients (16%) 
assigned to Ringer’s acetate (relative risk, 1.35; 95% CI, 
1.01 to 1.80; P  =  0.04), and 38 patients (10%) and 25 
patients (6%), respectively, had severe bleeding (relative 
risk, 1.52; 95% CI, 0.94 to 2.48; P = 0.09). Th e results were 
supported by multivariate analyses, with adjustment for 
known risk factors for death or acute kidney injury at 
baseline.
Conclusions
Patients with severe sepsis assigned to ﬂ uid resuscitation 
with HES 130/0.42 had an increased risk of death at day 
90 and were more likely to require renal replacement 
therapy compared with those receiving Ringer’s acetate.
Commentary
Fluid resuscitation is the cornerstone of treatment for 
patients with hypovolemia due to severe sepsis [1]. 
Colloids are used as they are thought to remain in the 
intravascular space longer, achieve faster circulatory 
stabilization [2], and require less amount of ﬂ uid for 
resuscitation compared with crystalloids [3]. Hydroxy-
ethyl starches (HESs) are synthetic colloids composed of 
amylopectin obtained from maize or potato starch and 
vary in their molecular weight, hydroxyethyl moieties, 
and in the ratio of C2 to C6 substitutions [4].
Results of clinical trials comparing resuscitation with 
colloids and crystalloids have been conﬂ icting. Com-
pared to modiﬁ ed Ringer’s lactate solution, resuscitation 
with HES 200/0.5 has been associated with increased 
risk of acute kidney injury (AKI) and requirement of 
renal replace ment therapy [5]. Another recent study 
(CRYSTMAS) found that resuscitation with low 
molecular weight HES 130/0.4 was associated with less 
time to hemodynamic stabilization and no diﬀ erence in © 2010 BioMed Central Ltd
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AKI, renal replacement therapy, and mortality compared 
to resuscitation with 0.9% saline [2]. However, this study 
was underpowered to detect diﬀ erences in mortality and 
establish safety of low molecular weight HES [6].
In this trial, Perner and colleagues [7] elegantly demon-
strate that patients with severe sepsis who received ﬂ uid 
resuscitation with HES 130/0.42 had increased mortality, 
increased risk of renal replacement therapy, a trend for 
increased bleeding, and increased blood product 
transfusion when compared to resuscitation with Ringers 
acetate. Interestingly, the study did not ﬁ nd that patients 
who received colloids require less amount of ﬂ uid when 
compared to crystalloids. Strengths of the study include 
being well-designed and adequately powered with broad 
inclusion criteria and low risk of bias due to double-
blinding and the multicenter nature of the trial. 
Importantly, the study measured patient-centered long-
term clinical outcomes, such us 90-day mortality and 
renal replacement therapy. Since Ringers acetate was a 
vehicle for HES in the intervention arm and was also the 
ﬂ uid in the control arm, it allows one to examine the 
causal eﬀ ect of HES on outcomes.
Th e few limitations of the study include a lack of a 
control for co-interventions and protocol violation. Of 69 
patients with protocol violation, 28 patients in the HES 
group and 41 patients in the Ringers acetate group 
received trial ﬂ uid at doses higher than the maximum 
speciﬁ ed in the protocol. Moreover, the criteria for 
initiation of renal replacement therapy were not pre-
speciﬁ ed in the study protocol, and the determination of 
requirement of ﬂ uid for resuscitation was based on 
clinician judgment rather than more objective hemo-
dynamic parameters.
Several important points related to the mechanisms of 
harmful eﬀ ects of HES deserve further consideration. 
First, the study showed that resuscitation with HES was 
associated with increased risk of AKI requiring renal 
replacement therapy compared to resuscitation with 
Ringer’s acetate (22% versus 16%, P  =  0.04). Th is study 
adds to the growing body of literature that suggests that 
HES, independent of the molecular weight or molar sub-
sti tution, increases the risk of AKI in an at-risk popu-
lation [8]. Although not well understood, potential mecha-
nisms by which HES might cause AKI include increased 
uptake of the starch into the proximal renal epithelial 
cells inducing ‘osmotic nephrosis-like lesions’, tubular 
obstruction caused by the production of hyperviscous 
urine, and renal interstitial inﬂ ammation [9].
Second, more patients receiving HES compared to 
Ringers acetate received blood product transfusions 
(relative risk, 1.20; 95% conﬁ dence interval (CI), 1.07 to 
1.36; P = 0.002) with higher volumes (cumulative median 
blood product volume, HES versus Ringers acetate, 1,340 
versus 1,055  ml; P  =  0.003). Multiple studies have 
demonstrated that HES molecules were associated with 
platelet dysfunction, interact with the coagulation 
cascade, and decrease factor VIII and von Willebrand 
factor levels [4] and ﬁ brin polymerization [10]. Import-
antly, increased bleeding tendency has also been ob-
served with use of low molecular weight starches [11].
Maize-derived and potato-derived HESs (as used in the 
study by Perner and colleagues) have structural diﬀ er-
ences due to diﬀ erences in the percentage of amylopectin 
(98% versus 75%) and C2/C6 substitution ratio (9:1 versus 
6:1) [4]. However, there is conﬂ icting evidence regarding 
whether this structural diﬀ erence has a clinical impact. 
For instance, while molecula r studies demonstrate 
biochemical diﬀ erences between these two starches [12], 
ex vivo studies show no diﬀ erence in bleeding eﬀ ects [10]. 
Th ese ﬁ ndings suggest that the risk of AKI and increased 
bleeding diathesis associated with HES is a class eﬀ ect of 
starches rather than its molecular weight or molar 
substitution [8].
Another recent large (n = 7,000) clinical trial (CHEST) 
found no diﬀ erence in 90-day mortality between HES 
130/0.40 and 0.9% saline in a heterogeneous group of 
critically ill patients [13]. However, the need for renal 
replacement therapy was higher among patients who 
received HES (7.0% versus 5.8%; relative risk, 1.21; 95% 
CI, 1.00 to 1.45; P = 0.04) compared to saline. Moreover, 
patients in the CHEST trial were less severely ill than 
patients in the study by Perner and colleagues, and in the 
subgroup analysis of patients with severe sepsis, there 
was a trend towards increased AKI and mortality in those 
who received HES.
More recently, when taking into consideration the 
absence of signiﬁ cant clinical beneﬁ t and the potential 
harmful eﬀ ect of starches based on the above studies, the 
2013 surviving sepsis campaign [14] recommended 
against using any HES in patients with severe sepsis. 
Another recently completed large (n = 3,000) clinical trial 
(CRYSTAL) [15] comparing crystalloids and colloids will 
provide additional insight into HES ﬂ uid resuscitation on 
clinical outcomes.
Recommendation
Fluid resuscitation with HES 130/0.4 increases risk of 
AKI requiring renal replacement therapy and mortality 
in patients with severe sepsis. Given evidence of harm 
and lack of signiﬁ cant clinical beneﬁ t, HES 130/0.4 
should not be used for ﬂ uid resuscitation for critically ill 
patients with severe sepsis.
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